军事医学2026，Vol.50Issue(4)：297-304,8.DOI:10.7644/j.issn.1674-9960.2025-00189
免疫检查点抑制剂联合抗血管生成药物治疗pMMR/MSS型结直肠癌的机制与临床研究进展
Research progress in mechanisms and clinical applications of immune checkpoint inhibitors combined with anti-angiogenic drugs in the treatment of pMMR/MSS colorectal cancer
摘要
Abstract
Colorectal cancer(CRC)is a highly prevalent malignant tumor worldwide.The emergence of immune checkpoint inhibitors(ICIs)has provided more therapeutic options.However,approximately 85%of proficient mismatch repair or microsatellite stable(pMMR/MSS)CRC cases have extremely low response rates to ICIs monotherapy.This resistance is attributed to the low tumor mutational burden,weak immunogenicity,and highly immunosuppressive tumor microenvironments,posing a major challenge to CRC immunotherapy.The combination of ICIs with anti-angiogenic drugs(AADs)(ICI-AAD therapy)has led to a novel therapeutic paradigm for CRC.This review summarizes the mechanisms behind and recent advances in the ICI-AAD therapy for pMMR/MSS CRC in general and key clinical studies such as AtezoTRIBE and CAPability-01 in particular.By elucidating the immunologically"cold tumor"pathophysiology of p MMR/MSS CRC and the synergistic interplay of ICI-AAD therapy,this study is expected to provide data for optimizing combinatorial immunotherapy for this subtype.关键词
结直肠癌/错配修复功能完整/微卫星稳定/免疫检查点抑制剂/抗血管生成药物/免疫抑制微环境Key words
colorectal cancer/mismatch repair proficient/microsatellite stability/immune checkpoint inhibitors/anti-angiogenic drugs/immunosuppressive microenvironment分类
医药卫生引用本文复制引用
袁汇,李红,宋扬..免疫检查点抑制剂联合抗血管生成药物治疗pMMR/MSS型结直肠癌的机制与临床研究进展[J].军事医学,2026,50(4):297-304,8.基金项目
陕西省科技厅基金项目(2025JC-YBMS-1011) （2025JC-YBMS-1011）
